Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 9/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1941895 | 0.85 | VCAM1 (0.47) | TRPV4VCAM1SLC22A12GPR35MEN1 | |
| SCHEMBL8960506 | 0.85 | VCAM1 (0.43) | TRPV4VCAM1SLC22A12GPR35MEN1 | |
| SCHEMBL8960510 | 0.83 | TRPV4 (0.43) | TRPV4VCAM1SLC22A12GPR35MEN1 | |
| SCHEMBL7466233 | 0.83 | MEN1 (0.42) | TRPV4VCAM1SLC22A12GPR35MEN1 | |
| SCHEMBL1263198 | 0.83 | CCR2 (0.45) | TRPV4VCAM1SLC22A12GPR35MEN1 | |
| SCHEMBL28284890 | 0.82 | TRPV4 (0.50) | TRPV4SLC22A12ALDH1A1MCL1 | |
| SCHEMBL7765655 | 0.81 | TRPV4 (0.60) | TRPV4VCAM1SLC22A12 | |
| SCHEMBL711705 | 0.79 | TRPV4 (0.42) | TRPV4SLC22A12ALDH1A1MAOAMAOB | |
| SCHEMBL16080223 | 0.79 | TRPV4 (0.46) | TRPV4SLC22A12MEN1KMT2A | |
| SCHEMBL29948948 | 0.79 | TRPV4 (0.46) | TRPV4SLC22A12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113717080-A | Synthesis method of 4-chloro-2-cyanobenzene sulfonyl chloride | 西安瑞联新材料股份有限公司 | 2021-11-30 | — | — | CN | claimed |
| US-20240158383-A1 | RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-3466934-B1 | SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-03-27 | — | — | EP | disclosed |
| EP-4301735-A1 | RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11634395-B2 | Sulfonamide compound or salt thereof | Taiho Pharmaceutial Co., Ltd. (JP) | 2023-04-25 | — | — | US | disclosed |
| EP-4061124-A1 | TRPV4 RECEPTOR LIGANDS | University of Utah Research Foundation (US) | 2022-09-28 | — | — | EP | disclosed |
| WO-2022187200-A1 | RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| CN-109563057-B | Sulfonamide compound or salt thereof | 大鹏药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| CN-113717080-A | Synthesis method of 4-chloro-2-cyanobenzene sulfonyl chloride | 西安瑞联新材料股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113717080-A | Synthesis method of 4-chloro-2-cyanobenzene sulfonyl chloride | 西安瑞联新材料股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| US-20200361883-A1 | Sulfonamide Compounds and Use Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-11-19 | — | — | US | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | TRPV4 1831/4885VCAM1 4825/4885SLC22A12 456/4885 |
| US-20240158383-A1 | RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM2B, RRM2, RNASE1 | TRPV4 4850/4885VCAM1 4083/4885SLC22A12 2130/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | TRPV4 1831/4885VCAM1 4825/4885SLC22A12 456/4885 |
| US-20200361883-A1 | Sulfonamide Compounds and Use Thereof | STS, SULT2A1, TPST2 | TRPV4 1822/4885VCAM1 4608/4885SLC22A12 704/4885 |
| US-11634395-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | TRPV4 1831/4885VCAM1 4825/4885SLC22A12 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.